-
Immunotherapy in the ElderlyImmune checkpoint inhibitors can be effective treatments for elderly people with some types of advanced cancer, but more information is needed on their risks and benefits in this group.
by Emma Yasinski
-
The Crowded Field of Checkpoint InhibitorsDrug developers behind currently approved checkpoint inhibitors discuss the pros and cons of competition in the field.
by Kate Yandell
-
What Is Hyper-Progression?Some researchers believe that immunotherapy occasionally causes cancer to grow faster, a phenomenon dubbed hyper-progression.
by Kate Yandell
-
First Immunotherapy Approved for Breast CancerMedical oncologist Leisha A. Emens discusses the significance of the first U.S. Food and Drug Administration approval of an immunotherapy treatment for breast cancer.
by Anna Azvolinsky
-
An Uncommon PartnershipThrough the Angiosarcoma Project, researchers are partnering with patients to learn about a rare cancer.
by Ashley P. Taylor
-
A New Type of Drug ApprovalAt the AACR Annual Meeting, researchers and regulators discuss what it means to tie approval of an immunotherapy to tumors' molecular characteristics, not to their tissues of origin.
by Kate Yandell
-
Non–Small Cell Lung Cancer Takes Center StageA trio of clinical trials at the AACR Annual Meeting spotlight new avenues for non-small cell lung cancer treatment.
by Brad Jones
-
Pembrolizumab Shows Further Promise for MelanomaIn a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected.
by Brad Jones
-
A Book Club for Cancer Survivors and CaregiversShare your experiences as we discuss “A Cure Within” in a Cancer Today Facebook group.
by Marci A. Landsmann
Scientists present data on the risks of immune checkpoint inhibitors so more patients can tap into the treatment.
by Marci A. Landsmann
Tissue and Liquid Biopsy for Targeted TherapyTailored treatments led to better outcomes than standard of care when biomarker results from liquid biopsy and tumor tissue aligned.
by Eric Fitzsimmons
Cancer Vaccines Show Promise in Early TrialsWhile mRNA vaccines offer a personalized approach to triggering an immune response, peptide vaccines could be a one-size-fits-all treatment. Researchers are exploring both options.
by Thomas Celona
Declining Breast Cancer Mortality in Younger WomenU.S. breast cancer deaths declined for women ages 20 to 49, which researchers credit to wider screening and better treatment.
by Kevin McLaughlin
-
Inaugural AACR IO Conference Kicks Off With Celebration of Immune CheckpointsImmune checkpoint icons James Allison and Arlene Sharpe shared their journeys and a look ahead on the opening night of the inaugural AACR IO conference.
-
A New Resource Provides a Sanctuary for Black TNBC PatientsThe Black TNBC Sanctuary was created to help Black women with triple-negative breast cancer get answers about their diagnosis and care.
Dr. Humberto M. Guiot: Targeting Pancreatic Cancer in a Community-Based Clinical Trial
